Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells

Journal of Experimental and Clinical Cancer Research

Volumn 27, Issue 1, 2008, Pages

  Fujiwara, Masao ^a   Izuishi, Kunihiko ^a   Sano, Takanori ^a   Hossain, Mohammad Akram ^a   Kimura, Shoji ^b   Masaki, Tsutomu ^b   Suzuki, Yasuyuki ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CASPASE 3; CISPLATIN; DNA FRAGMENT; PROTEIN KINASE B; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; ANTINEOPLASTIC AGENT; CHROMONE DERIVATIVE; ENZYME INHIBITOR; MORPHOLINE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; NUDE MOUSE; PANCREAS TUMOR; PHOSPHORYLATION; TUMOR CELL CULTURE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL PROLIFERATION; CHROMONES; CISPLATIN; DRUG SYNERGISM; ENZYME INHIBITORS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MORPHOLINES; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; TUMOR CELLS, CULTURED;

EID: 58149153118     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-27-76     Document Type: Article

References (27)

1. Combined Modality Therapy for pancreatic cancer. JY Tsai DA Iannitti H Safran, Seminars in Oncology 2003 30 Suppl 71 79 10.1016/S0093-7754(03)00273-2
2. Adjuvant therapy in pancreatic cancer: historical and current perspectives. JP Neoptolemos D Cunningham H Friess, Ann Oncol 2003 14 675 692 10.1093/annonc/mdg207 12702520
3. Randomised trial of gemcitabine versus flec regimen given intra-arterially for patients with unresectable pancreatic cancer. M Cantore G Fiorentini G Luppi, J Exp Clin Cancer Res 2003 22 4 Suppl 51 57 16767907
4. Molecular background of chemoresistance in pancreatic cancer. A Zalatnai J Molnár, In Vivo 2007 21 339 347 17436586
5. Cisplatin: mode of cytotoxic action and molecular basis of resistance. ZH Siddik, Oncogene 2003 22 7265 7279 10.1038/sj.onc.1206933 14576837
6. Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. N Itoh S Semba M Ito H Takeda S Kawata M Yamakawa, Cancer 2002 94 3127 3134 10.1002/cncr.10591 12115344
7. Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy. K Izuishi K Kato T Ogura T Kinoshita H Esumi, Cancer Res 2000 60 6201 6207 11085546
8. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. J Brognard AS Clark Y Ni PA Dennis, Cancer Res 2001 61 3986 3997 11358816
9. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. X Yang M Fraser UM Moll A Basak BK Tsang, Cancer Res 2006 66 3126 3136 10.1158/0008-5472.CAN-05-0425 16540663
10. Akt Involvement in Paclitaxel Chemoresistance of Human Ovarian Cancer Cells. SH Kim YS Juhnn YS Song, Ann N Y Acad Sci 2007 1095 82 89 10.1196/annals.1397.012 17404021
11. Activation of fibronectin/PI-3K/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cells. H Xing D Weng G Chen, Cancer Lett 2008 261 108 119 10.1016/j.canlet. 2007.11.022 18171600
12. Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models. T Ohta M Ohmichi T Hayasaka, Endocrinology 2006 147 1761 1769 10.1210/en.2005-1450 16396982
13. Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. J Hayakawa M Ohmichi H Kurachi, Cancer Res 2000 60 5988 5994 11085518
14. Targeting integrins and PI3K/Akt-mediated signal transduction pathways enhances radiation-induced anti-angiogenesis. S Ning Z Chen A Dirks, Radiat Res 2007 168 125 133 10.1667/RR0829.1 17722999
15. The combination of yondelis and cisplatin is synergistic against human tumor xenografts. M D'Incalci T Colombo P Ubezio, Eur J Cancer 2003 39 1920 1926 10.1016/S0959-8049(03)00490-8 12932672
16. Prognostic significance of activated AKT expression in soft-tissue sarcoma. Y Tomita T Morooka Y Hoshida, Clin Cancer Res 2006 12 3070 3077 10.1158/1078-0432.CCR-05-1732 16707604
17. Activated Akt as an indicator of prognosis in gastric cancer. C Cinti C Vindigni A Zamparelli, Virchows Arch 2008 453 449 455 10.1007/s00428-008-0676-8 18841391
18. Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. KS Chadha T Khoury J Yu, Ann Surg Oncol 2006 13 933 939 10.1245/ASO.2006.07.011 16788754
19. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression. SS Park SW Kim, Oncol Rep 2007 18 139 143 17549359
20. Phospho Akt mediates multidrug resistance of gastric cancer cells through regulation of P-gp, Bcl-2 and Bax. Z Han L Hong Y Han, J Exp Clin Cancer Res 2007 26 261 268 17725107
21. Reversal of multidrug resistance of gastric cancer cells by downregulation of Akt1 with Akt1 siRNA. Z Han L Hong K Wu, J Exp Clin Cancer Res 2006 25 601 606 17310852
22. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. AS Clark K West S Streicher PA Dennis, Mol Cancer Ther 2002 1 707 717 12479367
23. Targeting WNT, protein kinase B, and mitochondrial membrane integrity to foster cellular survival in the nervous system. ZZ Chong K Maiese, Histol Histopathol 2004 19 495 504 15024710
24. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer. G Wang E Reed QQ Li, Oncol Rep 2004 12 955 965 15492778
25. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. A Brozovic M Osmak, Cancer Lett 2007 251 1 16 10.1016/j.canlet.2006.10.007 17125914
26. Expression of survivin, bcl-2, P53 and bax in breast carcinoma and ductal intraepithelial neoplasia (DIN 1a). F Kayaselcuk TZ Nursal A Polat, J Exp Clin Cancer Res 2004 23 105 112 15149158
27. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). L Hu C Zaloudek GB Mills J Gray RB Jaffe, Clin Cancer Res 2000 6 880 886 10741711